KESETT

  1. Clinical Trials
  2. KESETT

Ketamine add-on therapy for Established Status Epilepticus Treatment Trial (KESETT)

Registered with ClinicalTrials.gov: NCT ID not yet assigned

NIH Project Number: 1UG3NS131532-01A1

Status: Start-up

Generalized convulsive status epilepticus (long-lasting convulsive seizures) is a dangerous but common neurologic emergency; it can cause respiratory depression and permanent brain damage. KESETT is a phase III randomized, double-blind clinical trial to test whether ketamine (1 or 3 mg/Kg) added to standard therapy, levetiracetam (60mg/Kg), is more effective than levetiracetam alone in treating status epilepticus after benzodiazepines have failed.